Literature DB >> 8085280

Nonparametric estimation of population characteristics of the kinetics of lithium from observational and experimental data: individualization of chronic dosing regimen using a new Bayesian approach.

N Taright1, F Mentré, A Mallet, R Jouvent.   

Abstract

A population analysis of the kinetics of lithium was performed from experimental and observational data in 113 subjects in order to propose a new approach for lithium dosage individualization. The kinetics of lithium is described by a two-compartment model. Age, body weight, height, and serum creatinine are included as covariates. Population analysis was performed by the nonparametric maximum likelihood method, which provides an estimate of the distribution of the five kinetic parameters and covariates. Mean lithium clearance was 1.50 L/h with a coefficient of variation (CV) of 38%, and was found to increase with body weight. Results were consistent with those of earlier studies and confirm a large interindividual variability. Data from a separate group of 35 patients were used to validate results: the estimated a priori and on covariate conditional distributions of the measured 24-h serum lithium concentration following a single dose were consistent with the corresponding measurements. A Bayesian approach for individualizing dosing schemes is proposed. This approach is based on minimization of a risk function expressing the deviation of the trough concentration at steady-state from the therapeutic range.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8085280     DOI: 10.1097/00007691-199406000-00006

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  10 in total

1.  Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.

Authors:  Aida Bustad; Dimiter Terziivanov; Robert Leary; Ruediger Port; Alan Schumitzky; Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Sequential updating of a new dynamic pharmacokinetic model for caffeine in premature neonates.

Authors:  Sandrine Micallef; Billy Amzal; Véronique Bach; Karen Chardon; Pierre Tourneux; Frédéric Y Bois
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method.

Authors:  F Mesnil; F Mentré; C Dubruc; J P Thénot; A Mallet
Journal:  J Pharmacokinet Biopharm       Date:  1998-04

4.  Population pharmacokinetics and pharmacodynamics: potential use for gathering dose-concentration-response.

Authors:  M Jerling
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

Review 5.  Differential pharmacokinetics of lithium in elderly patients.

Authors:  B A Sproule; B G Hardy; K I Shulman
Journal:  Drugs Aging       Date:  2000-03       Impact factor: 3.923

6.  Accuracy of the Pepin method to determine appropriate lithium dosages in healthy volunteers.

Authors:  E Stip; J Dufresne; B Boulerice; R Elie
Journal:  J Psychiatry Neurosci       Date:  2001-09       Impact factor: 6.186

Review 7.  Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals.

Authors:  R W Jelliffe; A Schumitzky; D Bayard; M Milman; M Van Guilder; X Wang; F Jiang; X Barbaut; P Maire
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 8.  Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective.

Authors:  E Samara; R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

9.  Implementation and evaluation of a stochastic control strategy for individualizing teicoplanin dosage regimen.

Authors:  M Tod; P Alet; O Lortholary; O Petitjean
Journal:  J Pharmacokinet Biopharm       Date:  1997-12

10.  Weighted target interval stochastic control methods with global optimization and their applications in individualizing therapy.

Authors:  Shaolin Ji; Yingzhi Zeng; Ping Wu; Edmund Jon Deoon Lee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-05-12       Impact factor: 2.410

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.